Superficial keratectomy with mitomycin-C for the treatment of salzmann’s nodules

Bowers, Patrick J; Price, Marianne O; Zeldes, Steven S; Price, Francis W

doi:10.1016/S0886-3350(02)01987-9

« Previous Next »Journal of Cataract & Refractive Surgery
Volume 29, Issue 7 , Pages 1302-1306, July 2003

Superficial keratectomy with mitomycin-C for the treatment of salzmann’s nodules☆

Presented at the ASCRS Symposium on Cataract, IOL and Refractive Surgery, Philadelphia, Pennsylvania, USA, June 2002.

Patrick J Bowers Jr., MD
- Price Vision Group, Indianapolis, Indiana, USA
- None of the authors has a financial or proprietary interest in any material or method mentioned.
Marianne O Price, PhD
- Price Vision Group, Indianapolis, Indiana, USA
- None of the authors has a financial or proprietary interest in any material or method mentioned.
Steven S Zeldes, MD
- Price Vision Group, Indianapolis, Indiana, USA
- None of the authors has a financial or proprietary interest in any material or method mentioned.
Francis W Price Jr., MD
- Reprint requests to Francis W. Price Jr., MD, Price Vision Group, 9002 North Meridian Street, Suite 207, Indianapolis, Indiana 46260, USA, Attn: Sherry Levy.
- Price Vision Group, Indianapolis, Indiana, USA
- None of the authors has a financial or proprietary interest in any material or method mentioned.

Accepted 11 November 2002.

Abstract

Purpose

To evaluate the success of treatment and prevention of recurrence of Salzmann’s nodules by superficial keratectomy with intraoperative mitomycin-C (MMC).

Setting

Price Vision Group, Indianapolis, Indiana, USA.

Methods

This retrospective consecutive case series comprised 30 eyes of 25 patients who had superficial keratectomy with MMC between January 1997 and June 2000 at a large tertiary-care center.

Results

Twenty-four patients reported improvement in their symptoms. The remaining patient lost 1 line of visual acuity. Ninety-seven percent of eyes maintained or improved best corrected visual acuity. No patient had a recurrence of Salzmann’s nodular degeneration over a mean follow-up of 28 months ± 15 (SD) (range 4.0 days to 4.1 years).